Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/6/2025

Management of Uncontrolled Exacerbations in Cystic Fibrosis

Introduction to Antibiotic Therapy

  • The Cystic Fibrosis Foundation explicitly states that there is insufficient evidence to recommend gentamicin inhalation for routine use in cystic fibrosis patients, and no standard protocol is recommended for this medication 1.
  • The Cystic Fibrosis Foundation strongly recommends tobramycin inhalation (Grade A recommendation) for cystic fibrosis patients aged 6 and above with moderate to severe lung disease and persistent P. aeruginosa infection 1, 2.
  • The protocol for tobramycin inhalation includes a dose of 300 mg twice daily via nebulizer, with a 28-day on and 28-day off cycle 1.
  • Tobramycin inhalation is indicated for patients with an FEV1 < 70% predicted and persistent P. aeruginosa infection, and has been shown to improve lung function, quality of life, and reduce exacerbations 2.

Intravenous Antibiotic Therapy

  • The American College of Chest Physicians recommends combination intravenous antibiotic therapy (usually antipseudomonal beta-lactam plus an aminoglycoside) for uncontrolled exacerbations 2.

Considerations for Combination Therapy

  • The Cystic Fibrosis Foundation concludes that there is insufficient evidence to recommend for or against the use of concurrent inhalation antibiotics in patients being treated with intravenous antibiotics for acute exacerbations (Grade I recommendation) 3, 4, 5, 6.
  • Potential issues with dual therapy include increased risk of toxicity, difficulty interpreting serum aminoglycoside levels, and lack of evidence for improved clinical outcomes 3, 4, 5, 7.

Chronic Therapy During Exacerbations

  • The Cystic Fibrosis Foundation recommends continuing chronic therapies for maintenance of lung health during treatment of acute exacerbations (Grade B recommendation) 2, 3, 4, 6, 7.
  • Therapies that should be continued include tobramycin inhalation, dornase alfa, hypertonic saline, and azithromycin oral (if already being used chronically) 2.

Safety Considerations

  • Bronchospasm is a significant concern with inhalation antibiotics, and pre-treatment with bronchodilators is recommended to prevent this 1, 8.
  • The use of high-dose NSAIDs (e.g. ibuprofen) with intravenous aminoglycosides may increase the risk of nephrotoxicity 3, 4, 5, 7.
  • Patients with renal dysfunction require close monitoring 7.

Location of Care

  • The Cystic Fibrosis Foundation recommends against administering intravenous antibiotics in non-hospital settings unless resources and support equivalent to a hospital setting can be ensured for the treatment of acute exacerbations (Grade I recommendation) 3, 7.

Cystic Fibrosis Management

Inhalation Therapy

  • The European Respiratory Journal notes that gentamicin intravenous formulation contains additives like phenol, which can cause toxicity in the airways when aerosolized 9
  • The American Journal of Respiratory and Critical Care Medicine recommends monitoring serum tobramycin levels when patients receive intravenous aminoglycosides concurrently with high-dose tobramycin inhalation due to the risk of increased toxicity 10, 11

Azithromycin Protocol

  • The American Journal of Respiratory and Critical Care Medicine suggests that azithromycin should be continued during acute exacerbations of pulmonary disease as part of chronic maintenance therapy (Grade B recommendation) 10, 11
  • The Cystic Fibrosis Foundation recommends continuing chronic therapies, including azithromycin, during acute exacerbations of pulmonary disease 10, 11

REFERENCES

1

Inhaled Tobramycin vs. Colistin in Bronchiectasis: Guideline Recommendations [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

2

Antibiotic Therapy for Cystic Fibrosis [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

3

cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. [LINK]

American Journal of Respiratory and Critical Care Medicine, 2009

4

cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. [LINK]

American Journal of Respiratory and Critical Care Medicine, 2009

5

cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. [LINK]

American Journal of Respiratory and Critical Care Medicine, 2009

6

cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. [LINK]

American Journal of Respiratory and Critical Care Medicine, 2009

7

cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. [LINK]

American Journal of Respiratory and Critical Care Medicine, 2009

8

Inhaled Antibiotics for Non-Cystic Fibrosis Bronchiectasis [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

10

cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. [LINK]

American Journal of Respiratory and Critical Care Medicine, 2009

11

cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. [LINK]

American Journal of Respiratory and Critical Care Medicine, 2009